Compounds for treating proliferative disorders

Abstract

A compound of formula (I) or a pharmaceutically acceptable salt or solvate or physiologically hydrolysable, solubilizing or immobilizable derivative thereof; wherein: any one or two of X., X2 and X3 is a N atom and the remaining two or one of X, Xand Xare independently CR; Y is selected from SOand SO; R, R, R, and Rand the one or two Rgroups are each independently selected from H and R, Ris selected from R, alkyl, aryl, heteroaryl and combinations of two or more thereof and combinations with one or more R, or Ris one or more moieties RSinking one or more alkyl, alkoxy, aryl, heteroaryl or Ror Rgroups or combinations thereof, directly or via a moiety selected from alkylene, arylene, heteroarylene or combinations thereof, wherein alkyl, aryl, heteroaryl groups or moieties thereof may be substituted with one or more groups R, or Ris selected from a group R; Ris selected from 0-, N—, NH—, N═C, CO—, C00-, CON—, CONH—, S0-, S0N—, S0NH—; Ris selected from halogen, NH, N0, CN, OH, COOH, CONH, C(═NH)NH, S0H, S0NH, S0CH, OCH, OCHCH, CF; Rand Rcomprise one or more solubilizing moieties independently chosen from i) neutral hydrophilic groups, ii) ionisable organic acids, iii) ionisable organic bases, iv} chemical functions or moieties providing covalent or non-covalent attachment or binding to a solid phase or an immobile receptor and combinations thereof; R, Rand Rare each independently selected from H and R, or two of Rto Rare linked to form a cyclic ether or amine containing one or more additional oxygen or nitrogen atoms. The compound may be used for treating a condition mediated by one or more enzymes selected from AKT, Aurora kinase, BCR-ABL, CDK, FLT, GSK3, IKK, JAK, MAPK, PDGF, PI3K, PKA, PKB, PKC, PLK, Src and VEGF family enzymes, or for treating cancer or other proliferative disorder, or for inhibiting growth of cancer cells, or for inducing apoptosis of cancer cells, in a human or animal subject.